retatrutide phase 2 trial type 2 diabetes results 2024 Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a retatrutide type 2 diabetes phase

Based on application, the type 2 diabetes mellitus segment is projected to dominate in 2026

Rashmi Advani, director of bariatric endoscopy at Mount Sinais Center for Interventional Endoscopy and an assistant professor of medicine at the Icahn School of Medicine, said GLP-1 medications address one barrier to patients considering bariatric surgery or bariatric endoscopy access to health care facilities that provide this type of care

Weight loss drugs containing GLP-1 agonists have exploded in popularity in recent years, gaining the interest of consumers for usage far beyond the FDA-approved purpose to treat type 2 diabetes and obesity

Future Potential As research techniques advance, we may discover important functions for GLP-3